Overview

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2028-11-29

Target enrollment:

Participant gender:

Summary

Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Drug Therapy
Immunotherapy
Radiotherapy
surufatinib
toripalimab